A Phase 2 Trial of Glofitamab for Minimal Residual Disease in Patients With Large B-cell Lymphoma

NCT06670105 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped PI Request

Conditions

B-cell Lymphoma

Interventions

DRUG: Glofitamab

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]